0 93

Cited 0 times in

Recurrence Risk-Scoring Model for Stage I Adenocarcinoma of the Lung

Authors
 Hee Chul Yang  ;  Hyeong Ryul Kim  ;  Jae Yong Park  ;  Ju Sik Yun  ;  Kook Joo Na  ;  Young Mog Shim  ;  Jhingook Kim  ;  Jong Mog Lee  ;  Moon Soo Kim  ;  Jae Ill Zo  ;  Se Hoon Choi  ;  Dong Kwan Kim  ;  Seong Yong Park  ;  Mi Kyung Bae  ;  Kyung Young Chung  ;  Jin-Haeng Chung  ;  Ho-Young Lee  ;  Soyeon Ahn  ;  Sukki Cho  ;  Kwhanmien Kim  ;  Sanghoon Jheon 
Citation
 Annals of Surgical Oncology, Vol.22(12) : 4089-4097, 2015 
Journal Title
 Annals of Surgical Oncology 
ISSN
 1068-9265 
Issue Date
2015
Abstract
PURPOSE: The aim of this retrospective, multicenter study was to develop a recurrence risk-scoring model in patients with curatively resected stage I lung adenocarcinoma (ADC). METHODS: Clinicopathologic and outcome data for a development cohort of 1,700 patients with pathologic stage I ADC from four institutions resected between January 2000 and December 2009 were evaluated. A phantom study was performed for correction of inter-institutional differences in positron emission tomography-standardized uptake value (PET-SUV). A nomogram for recurrence prediction was developed using Cox proportional hazards regression. This model was validated in a cohort of 460 patients in two other hospitals. The recurrence rate was 21.0 % for the development cohort and 22.1 % for the validation cohort. RESULTS: In multivariable analysis, three independent predictors for recurrence were identified: pathologic tumor size (hazard ratio [HR] 1.03, 95 % CI 1.017-1.048; p < 0.001), corrected PET-SUV (HR 1.08, 95 % CI 1.051-1.105; p < 0.001), and lymphovascular invasion (HR 1.65, 95 % CI 1.17-2.33; p = 0.004). The nomogram was made based on these factors and a calculated risk score was accorded to each patient. Kaplan-Meier analysis of the development cohort showed a 5-year recurrence-free survival (RFS) of 83 % (95 % CI 0.80-0.86) in low-risk patients and 59 % (95 % CI 0.54-0.66) in high-risk patients with the highest 30 percentile scores. The concordance index was 0.632 by external validation. CONCLUSIONS: This recurrence risk-scoring model can be used to predict the RFS for pathologic stage I ADC patients using the above three easily measurable factors. High-risk patients need close follow-up and can be candidates for adjuvant chemotherapy.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/141796
DOI
10.1245/s10434-015-4411-9
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Thoracic and Cardiovascular Surgery (흉부외과학교실)
Yonsei Authors
정경영(Chung, Kyung Young)
사서에게 알리기
  feedback
Full Text
http://link.springer.com/article/10.1245%2Fs10434-015-4411-9
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse